Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Implications of local osteoporosis on the efficacy of anti-resorptive drug treatment: a 3-year follow-up finite element study in risedronate-treated women.

Anitha D, Kim KJ, Lim SK, Lee T.

Osteoporos Int. 2013 Dec;24(12):3043-51. doi: 10.1007/s00198-013-2424-4. Epub 2013 Jul 2.

PMID:
23818209
2.

Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women.

Osaki M, Tatsuki K, Hashikawa T, Norimatsu T, Chiba K, Motokawa S, Furuichi I, Doiguchi Y, Aoyagi K, Shindo H.

Osteoporos Int. 2012 Feb;23(2):695-703. doi: 10.1007/s00198-011-1556-7. Epub 2011 Mar 11.

3.

Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.

Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C.

Osteoporos Int. 2014 Jul;25(7):1953-61. doi: 10.1007/s00198-014-2692-7. Epub 2014 Mar 28.

PMID:
24676847
4.

Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.

Palomba S, Orio F Jr, Manguso F, Falbo A, Russo T, Tolino A, Tauchmanovà L, Colao A, Doldo P, Mastrantonio P, Zullo F.

Osteoporos Int. 2005 Sep;16(9):1141-9. Epub 2005 Jun 1.

PMID:
15928801
5.

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis.

Masud T, McClung M, Geusens P.

Clin Interv Aging. 2009;4:445-9. Epub 2009 Nov 18.

6.

Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.

Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S, Morelli V, Beck-Peccoz P, Chiodini I.

Osteoporos Int. 2014 Apr;25(4):1401-10. doi: 10.1007/s00198-014-2619-3. Epub 2014 Feb 8.

PMID:
24510095
7.

Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.

Roux C, Goldstein JL, Zhou X, Klemes A, Lindsay R.

Osteoporos Int. 2012 Jan;23(1):277-84. doi: 10.1007/s00198-011-1574-5. Epub 2011 Mar 2.

PMID:
21365461
8.

Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.

Takakuwa M, Iwamoto J, Itabashi K.

Clin Drug Investig. 2012 Feb 1;32(2):121-9. doi: 10.2165/11597990-000000000-00000.

PMID:
22185631
9.

Multi-site bone ultrasound measurements in elderly women with and without previous hip fractures.

Karjalainen JP, Riekkinen O, Töyräs J, Hakulinen M, Kröger H, Rikkonen T, Salovaara K, Jurvelin JS.

Osteoporos Int. 2012 Apr;23(4):1287-95. doi: 10.1007/s00198-011-1682-2. Epub 2011 Jun 9.

PMID:
21656263
10.

The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT.

Ito M, Oishi R, Fukunaga M, Sone T, Sugimoto T, Shiraki M, Nishizawa Y, Nakamura T.

Osteoporos Int. 2014 Mar;25(3):1163-72. doi: 10.1007/s00198-013-2596-y. Epub 2013 Dec 18.

11.

Hip structural geometry and incidence of hip fracture in postmenopausal women: what does it add to conventional bone mineral density?

LaCroix AZ, Beck TJ, Cauley JA, Lewis CE, Bassford T, Jackson R, Wu G, Chen Z.

Osteoporos Int. 2010 Jun;21(6):919-29. doi: 10.1007/s00198-009-1056-1. Epub 2009 Sep 15.

12.

The effects of bazedoxifene on bone structural strength evaluated by hip structure analysis.

Beck TJ, Fuerst T, Gaither KW, Sutradhar S, Levine AB, Hines T, Yu CR, Williams R, Mirkin S, Chines AA.

Bone. 2015 Aug;77:115-9. doi: 10.1016/j.bone.2015.04.027. Epub 2015 Apr 23.

PMID:
25917574
13.

Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial.

Yang L, Sycheva AV, Black DM, Eastell R.

Osteoporos Int. 2013 Jan;24(1):329-38. doi: 10.1007/s00198-012-2200-x. Epub 2012 Nov 6.

PMID:
23128664
14.

Femoral neck trabecular bone: loss with aging and role in preventing fracture.

Thomas CD, Mayhew PM, Power J, Poole KE, Loveridge N, Clement JG, Burgoyne CJ, Reeve J.

J Bone Miner Res. 2009 Nov;24(11):1808-18. doi: 10.1359/jbmr.090504.

15.

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY; Hip Intervention Program Study Group..

N Engl J Med. 2001 Feb 1;344(5):333-40.

16.

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.

Abelson A, Ringe JD, Gold DT, Lange JL, Thomas T.

Osteoporos Int. 2010 Jun;21(6):1021-9. doi: 10.1007/s00198-009-1046-3. Epub 2009 Sep 1.

17.

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.

Int J Clin Pharmacol Res. 2004;24(1):1-10.

PMID:
15575171
18.

Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.

Lindsay R, Watts NB, Lange JL, Delmas PD, Silverman SL.

Osteoporos Int. 2013 Aug;24(8):2345-52. doi: 10.1007/s00198-013-2332-7. Epub 2013 Apr 24. Erratum in: Osteoporos Int. 2013 Aug;24(8):2375-6.

PMID:
23612793
19.

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

Borgström F, Ström O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA.

Osteoporos Int. 2010 Mar;21(3):495-505. doi: 10.1007/s00198-009-0989-8. Epub 2009 Jun 30.

PMID:
19565175
20.

Supplemental Content

Support Center